Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Nedisertib Recombinant Mouse Monoclonal Antibody (4C12)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 1
Nedisertib Antibody (MA566243) in SDS-PAGE
SDS-PAGE characterization of Nedisertib under reducing conditions. Lane M: Protein marker (kDa); Lane M3814: Purified Nedisertib Recombinant Monoclonal (Product # MA566243). Nedisertib showing heavy chain (~50 kDa) and light chain (~25 kDa). Gels were stained with Coomassie Brilliant Blue R-350.
产品信息
MA566243
产品规格
种属反应
Chemical
宿主/亚型
Mouse
/ IgG
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
克隆号
4C12
抗原
Conjugate of M3814 hapten and KLH.
偶联物
形式
Liquid
浓度
4.8 mg/mL
纯化类型
Protein G
保存液
PBS
内含物
0.09% sodium azide
保存条件
-20°C
运输条件
Ambient (domestic); Wet ice (international)
靶标信息
Nedisertib, also known as M3814, is a potent and selective inhibitor of DNA-dependent protein kinase (DNA-PK), currently under phase 2 clinical trials. This kinase plays a crucial role in the non-homologous end joining pathway of DNA repair, making nedisertib a promising candidate for cancer therapy, particularly in combination with radiotherapy and chemotherapy agents like capecitabine. The drug's mechanism involves modulating ABCG2-mediated multidrug resistance, which is a significant challenge in cancer treatment. Nedisertib's ability to inhibit DNA-PK enhances the efficacy of radiotherapy by preventing the repair of radiation-induced DNA damage in tumor cells, thereby promoting cell death. This approach leverages the immunostimulatory effects of ionizing radiation, which activates both adaptive and innate immune responses, further aiding in tumor eradication.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
